Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

108.86
-2.0000-1.80%
Post-market: 108.860.00000.00%19:59 EDT
Volume:608.44K
Turnover:66.68M
Market Cap:5.36B
PE:-18.87
High:112.25
Open:110.18
Low:108.03
Close:110.86
Loading ...

Axsome Therapeutics: Strategic Launch and Study Upside Drive Buy Rating

TIPRANKS
·
04 Feb

Axsome Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
04 Feb

BofA Adjusts Price Target on Axsome Therapeutics to $143 From $122

MT Newswires Live
·
03 Feb

Axsome Therapeutics price target raised to $190 from $180 at Truist

TIPRANKS
·
03 Feb

RBC Lifts Price Target on Axsome Therapeutics to $143 From $139, Keeps Outperform Rating

MT Newswires Live
·
03 Feb

Axsome Therapeutics price target raised to $132 from $116 at Baird

TIPRANKS
·
03 Feb

U.S. RESEARCH ROUNDUP-Abbvie, Comstock Resources, Sherwin-Williams

Reuters
·
03 Feb

Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises

Zacks
·
31 Jan

Buy Rating for Axsome Therapeutics Driven by Symbravo Approval and Strategic Market Approach

TIPRANKS
·
31 Jan

Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
31 Jan

Axsome Therapeutics Hosts Symbravo® FDA Approval Virtual Investor Event With Expert Thought Leader

THOMSON REUTERS
·
31 Jan

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

GlobeNewswire
·
31 Jan

Axsome Shares Up Post Market After Hitting Record High on FDA Approval

Dow Jones
·
31 Jan

US FDA approves Axsome Therapeutics' migraine drug

Reuters
·
31 Jan

Axsome Therapeutics announces FDA approval of Symbravo

TIPRANKS
·
31 Jan

Axsome Therapeutics Announces FDA Approval of Symbravo® (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine With or Without Aura in Adults

THOMSON REUTERS
·
31 Jan

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

GlobeNewswire
·
31 Jan

Axsome Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
30 Jan

Axsome Therapeutics price target raised to $155 from $125 at TD Cowen

TIPRANKS
·
29 Jan

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
29 Jan